Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Up 306.0% in August

Key Points

• Sino Biopharmaceutical experienced a dramatic increase in short interest, rising by 306.0% in August, with a total of 49,345,500 shares sold short as of August 31st.
• The company's stock price increased by 3.1% to reach $1.24, reflecting a significant trading activity compared to its average volume.
• Sino Biopharmaceutical operates as a pharmaceutical conglomerate in China, focusing on various segments including oncology and liver disease medications.

Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 49,345,500 shares, a growth of 306.0% from the August 15th total of 12,155,500 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days. Approximately 0.3% of the shares of the company are short sold. Approximately 0.3% of the shares of the company are short sold. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.

Sino Biopharmaceutical Price Performance

Sino Biopharmaceutical stock remained flat at $1.24 during midday trading on Friday. Sino Biopharmaceutical has a 52-week low of $0.37 and a 52-week high of $1.24. The stock's 50 day moving average is $0.94 and its 200-day moving average is $0.66.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.